Non-marine Paleogene sequences, Salta Group, Northwest Argentina

Los depósitos de edad paleógena forman la culminación de la cuenca distensiva originada desde el Cretácico inferior hasta el Eoceno en el noroeste argentino. El desarrollo del rift presenta extensión regional y abarca parte de la sedimentación ocurrida en forma contemporánea en Bolivia, Paraguay y Chile. Durante el desarrollo de cuenca con subsidencia termal, se formaron tres secuencias deposicionales constituidas por las Formaciones Mealla, Maíz Gordo y Lumbrera, que integran el Subgrupo Santa Bárbara del Grupo Salta. Estas unidades presentan características sedimentológicas similares que le confieren cierta ciclicidad a este período. La distribución de los sedimentos y la asociación de facies del Subgrupo Santa Bárbara señalan una cuenca cerrada con sedimentación aluvial hacia los bordes y formación de lagos en el área central. En la Formación Mealla se han reconocido cuatro asociaciones de facies (FA) que en gran medida identifican los ambientes sedimentarios que la integran. En posiciones de bordes de cuenca, por ejemplo sobre el borde del arco Traspampeano, se han identificado las asociaciones de facies 1 y 2 (FA1 y FA2) formadas por las litofacies Gm, Gt, Gp, Sm, Sp, Sm, Se, Fm, Fl, Fsc y P. Se ha interpretado un ambiente de abanicos aluviales proximales a distales con buen desarrollo de las facies de llanura de inundación y formación de paleosuelos carbonáticos. Hacia el centro de la cuenca se reconoció la asociacion de facies FA 3, integrada por Sp, St, Sr, Fm y P que indican sistemas fluviales arenosos interpretados como ríos entrelazados arenosos y meandrosos de grano fino. La FA 4 representa la deposición en medio subácueo, integrada por las litofacies F, Sw, Cm, E y Bs e interpretada como lago salino a lago abierto de agua dulce. En la Formación Maíz Gordo el esquema es muy similar. Hacia los bordes de cuenca se reconoció la asociación de facies FA5, integrada por las litofacies Gm, Sm, St, Gh, Gp y Sp, e interpretada como abanico aluvial proximal y ríos entrelazados profundos. Lateralmente se reconoció la asociación de facies FA 6, formada por las litofacies Sp, St, Sr, Fm, Fl y P que representa la formación de ríos entrelazados arenosos. En el centro de la cuenca se identificaron las asociaciones de facies FA 7 y FA 8, integradas por las litofacies Fm, Bs, Go, Ll, F, Lwl, Sw y P que indican sedimentación subácuea de tipo lacustre con extensa formación de facies litorales carbonáticas e internas de tipo meromíctico. La Formación Lumbrera representa la culminación de la sedimentación en el Grupo Salta, caracterizada por sedimentación de tipo pelítico y frecuentes paleosuelos carbonáticos en el área con sedimentación aluvial. Está integrada por las asociaciones de facies FA 9, Sp, St, Se, Fm y P e interpretada como ríos meandrosos de arena gruesa, FA 10, Sp, St, Sr, Ss, Se, Sh, Sl, Fl y Fm cuya asociación representa ríos meandrosos finos en los que se distinguen los depósitos de sobrebanco, albardón y desborde. En el centro de la cuenca se reconocieron las FA 11 y FA 12, integradas por las litofacies St, Sr, F, Sw, Fm, Ll y Bs que representan la acumulación en un sistema lacustre clástico de tipos holomíctico y meromíctico. El contenido paleontológico tanto de palinomorfos como de vertebrados revela variaciones climáticas fluctuantes desde situaciones de aridez hasta condiciones de mayor humedad, lo que sustenta las interpretaciones sedimentológicas realizadas. En la base de cada unidad se ha interpretado condiciones de aridez que pasan gradualmente a situaciones de mayor humedad hacia el tope.Deposits of Paleogene age form the culmination of the distensive basin developed from Lower Cretaceous up to Eocene times in North west A rgentina. The rift development shows a regional extension, and includes part of the sedimentation which occurred contemporaneously in Bolivia, Paraguay and Chile. During development of the sag basin, three depositional sequences were laid down. These were the Mealla, Maíz Gordo and Lumbrera Formations, which make up the Santa Bárbara Subgroup of the Salta Group. These units present similar sedimentological characteristics, which gives this period a cyclic arrangement . The sedimentary distribution and the arrangement of facies point to a closed basin, with alluvial sedimentation toward its borders, and the formation of lakes in its central area. Each unit shows a particular pattern of river systems, from perennial sand-gravel bed braided streams to fine-grained meandering streams, and pattern of the lake originated there. It is recognized that each lacustrine basin started to develop under shallow conditions in an arid climate, and then evolved to deeper lakes, which reached stratification of the water mass. The paleontologic content, especially the palinomorphs, records these fluctuating climatic changes, from arid situations to more humid conditions

Full activation of Enterococcus faecalis gelatinase by a C-terminal proteolytic cleavage

Enterococci account for nearly 10% of all nosocomial infections and constitute a significant treatment challenge due to their multidrug resistance properties. One of the well-studied virulence factors of Enterococcus faecalis is a secreted bacterial protease, termed gelatinase, which has been shown to contribute to the process of biofilm formation. Gelatinase belongs to the M4 family of bacterial zinc metalloendopeptidases, typified by thermolysin. Gelatinase is synthesized as a preproenzyme consisting of a signal sequence, a putative propeptide, and then the mature enzyme. We determined that the molecular mass of the mature protein isolated from culture supernatant was 33,030 Da, which differed from the predicted molecular mass, 34,570 Da, by over 1,500 Da. Using N-terminal sequencing, we confirmed that the mature protein begins at the previously identified sequence VGSEV, thus suggesting that the 1,500-Da molecular mass difference resulted from a C-terminal processing event. By using mutants with site-directed mutations within a predicted C-terminal processing site and mutants with C-terminal deletions fused to a hexahistidine tag, we determined that the processing site is likely to be between residues D304 and 1305 and that it requires the Q306 residue. The results suggest that the E. faecalis gelatinase requires C-terminal processing for full activation of protease activity, making it a unique enzyme among the members of the M4 family of proteases of gram-positive bacteria.Instituto de Biotecnologia y Biologia Molecula

Corneal involvement in rheumatoid arthritis: an vivo confocal study

PURPOSE. To analyze the in vivo morphology of corneal cells and nerves in patients with rheumatoid arthritis (RA), with or without secondary Sj\uf6gren\u2019s syndrome (SSII), and to investigate the correlations between corneal alterations and RA activity. METHODS. Fifty patients with RA and 30 age- and gender-matched control subjects were studied. SSII was diagnosed according to the American-European Consensus Group criteria, and RA activity was evaluated by the Lansbury index (LI). Confocal microscopy was used to investigate corneal thickness, the number of epithelial and stromal cells, and keratocyte hyperreflectivity. In addition, the sub-basal plexus was assessed for the number, tortuosity, and reflectivity of the nerve fibers and the presence of beadlike formations. RESULTS. Sixteen percent of patients with RA also had SSII. Between the SSII and non-SSII groups, no significant differences were found in the LI or in the clinical and confocal variables. Significant differences were present between patients with RA and control subjects for all the variables studied except nerve reflectivity. In patients with RA with and without SSII, LI correlated significantly with the number of beadlike formations and the number of hyperreflective, activated keratocytes. CONCLUSIONS. Confocal microscopy of patients with RA showed several changes in corneal cells and nerves. The number of beadlike formations and the number of activated keratocytes could be interpreted as confocal signs of ocular surface disease activity. These correlations with the index of systemic disease activity, LI, may provide insight regarding the pathogenic mechanisms of dry eye in patients with RA

Integrated Bimodal Fitting for Unilateral CI Users with Residual Contralateral Hearing

Background: The aim of this study was to compare, in users of bimodal cochlear implants, the performance obtained using their own hearing aids (adjusted with the standard NAL-NL1 fitting formula) with the performance using the Phonak Naìda Link Ultra Power hearing aid adjusted with both NAL-NL1 and a new bimodal system (Adaptive Phonak Digital Bimodal (APDB)) developed by Advanced Bionics and Phonak Corporations. Methods: Eleven bimodal users (Naìda CI Q70 + contralateral hearing aid) were enrolled in our study. The users’ own hearing aids were replaced with the Phonak Naìda Link Ultra Power and fitted following the new formula. Speech intelligibility was assessed in quiet and noisy conditions, and comparisons were made with the results obtained with the users’ previous hearing aids and with the Naída Link hearing aids fitted with the NAL-NL1 generic prescription formula. Results: Using Phonak Naìda Link Ultra Power hearing aids with the Adaptive Phonak Digital Bimodal fitting formula, performance was significantly better than that with the users’ own rehabilitation systems, especially in challenging hearing situations for all analyzed subjects. Conclusions: Speech intelligibility tests in quiet settings did not reveal a significant difference in performance between the new fitting formula and NAL-NL1 fittings (using the Naída Link hearing aids), whereas the performance difference between the two fittings was very significant in noisy test conditions

Full activation of Enterococcus faecalis gelatinase by a C-terminal proteolytic cleavage

Enterococci account for nearly 10% of all nosocomial infections and constitute a significant treatment challenge due to their multidrug resistance properties. One of the well-studied virulence factors of Enterococcus faecalis is a secreted bacterial protease, termed gelatinase, which has been shown to contribute to the process of biofilm formation. Gelatinase belongs to the M4 family of bacterial zinc metalloendopeptidases, typified by thermolysin. Gelatinase is synthesized as a preproenzyme consisting of a signal sequence, a putative propeptide, and then the mature enzyme. We determined that the molecular mass of the mature protein isolated from culture supernatant was 33,030 Da, which differed from the predicted molecular mass, 34,570 Da, by over 1,500 Da. Using N-terminal sequencing, we confirmed that the mature protein begins at the previously identified sequence VGSEV, thus suggesting that the 1,500-Da molecular mass difference resulted from a C-terminal processing event. By using mutants with site-directed mutations within a predicted C-terminal processing site and mutants with C-terminal deletions fused to a hexahistidine tag, we determined that the processing site is likely to be between residues D304 and 1305 and that it requires the Q306 residue. The results suggest that the E. faecalis gelatinase requires C-terminal processing for full activation of protease activity, making it a unique enzyme among the members of the M4 family of proteases of gram-positive bacteria.Instituto de Biotecnologia y Biologia Molecula

IRST SiPM characterizations and application studies

This paper reports on work undertaken, in collaboration with ITC-IRST at Trento, to characterize and test the silicon photomultiplers produced by them, with a view to their future application in high energy and astrophysics experiments. Results of static and dynamic measurents with various IRST devices under controlled climatic conditions, together with measurements with SiPMs from other distributors are reported and discussed with emphasis on progress in the understanding of operational principles and the reduction of noise. Results from the test beam application of the SiPMs are also reported and future plans are discusse

Prompt dipole radiation in fusion reactions

The prompt gamma ray emission was investigated in the 16A MeV energy region by means of the 36,40Ar+96,92Zr fusion reactions leading to a compound nucleus in the vicinity of 132Ce. We show that the prompt radiation, which appears to be still effective at such a high beam energy, has an angular distribution pattern consistent with a dipole oscillation along the symmetry axis of the dinuclear system. The data are compared with calculations based on a collective bremsstrahlung analysis of the reaction dynamics

Mapping the demise of collective motion in nuclei at high excitation energy

High energy gamma-rays from the 116Sn + 24Mg reaction at 23A MeV were measured using the MEDEA detector at LNS – INFN Catania. Combining this new data with previous measurements yields a detailed view of the quenching of the Giant Dipole Resonance as a function of excitation energy in nuclei of mass A in the range 120÷132. The transition towards the disappearance of the dipole strength, which occurs around 230 MeV excitation energy, appears to be remarkably sharp. Current phenomenological models give qualitative explanations for the quenching but cannot reproduce its detailed features. Keywords: Giant Dipole Resonance, Hot nuclei, Fusion reactions, Statistical Mode

Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners.

Systemic sclerosis (SSc) is a rare disabling autoimmune disease with a similar mortality to many cancers. Two randomized controlled trials of autologous hematopoietic stem cell transplantation (AHSCT) for SSc have shown significant improvement in organ function, quality of life and long-term survival compared to standard therapy. However, transplant-related mortality (TRM) ranged from 3-10% in patients undergoing HSCT. In SSc, the main cause of non-transplant and TRM is cardiac related. We therefore updated the previously published guidelines for cardiac evaluation, which should be performed in dedicated centers with expertize in HSCT for SSc. The current recommendations are based on pre-transplant cardiopulmonary evaluations combining pulmonary function tests, echocardiography, cardiac magnetic resonance imaging and invasive hemodynamic testing, initiated at Northwestern University (Chicago) and subsequently discussed and endorsed within the EBMT ADWP in 2016

POS0054 THE IMPACT AND OUTCOME OF COVID-19 ON SYSTEMIC SCLEROSIS PATIENTS FROM THE EUROPEAN SCLERODERMA TRIAL AND RESEARCH GROUP (EUSTAR)

Background:Coronavirus disease-19 (COVID-19) has been a major clinical challenge worldwide. Sex, age and comorbidities have been associated with worse outcome in the general population. Systemic sclerosis (SSc) is a severe, autoimmune disease with frequent multi-organ involvement.Objectives:To assess the impact of COVID-19 and to determine factors associated with worse outcome in SSc patients from the European Scleroderma Trial and Research (EUSTAR) database.Methods:SSc patients from the EUSTAR database with COVID-19 were prospectively collected between 15.03.-31.12.2020. Two outcomes were chosen: (1) hospitalization; and (2) severe outcome defined as either non-invasive ventilation, mechanical ventilation/extracorporeal membrane oxygenation (ECMO) or death. General risk factors assessed were sex, age and number of comorbidities. SSc related risk factors were SSc subtype, autoantibodies, disease duration, SSc associated organ manifestations including interstitial lung disease (ILD), pulmonary arterial hypertension (PAH), cardiac, gastrointestinal (GI), and musculoskeletal involvement; digital ulcers (DU), CRP at last visit, renal disease (scleroderma renal crisis and SSc associated renal insufficiency), modified Rodnan skin score (mRSS) and immunosuppressive treatment. Descriptive statistics and logistic regression models were applied.Results:In total, 178 European SSc patients with COVID-19 were registered with a median observation time of 5.5 weeks (Table 1). 95 patients (53%) could recall SAR-Cov-2 contact, while 47 (26%) had no contact. 156 (88%) were symptomatic at COVID-19 onset with fever, cough, malaise and dyspnea being most prevalent. Over the disease course, 63 (36%) developed pneumonia. In total, 67/176 (38%) were hospitalized which were in 84% due to COVID-19. 41/170 (24%) had a severe outcome including 21 (12%) deaths. 128 (72%) recovered completely, while 14 (8%) complained of sequela, with 7 (50%) stating respiratory complications. Age, non-SSc comorbidities, presence of ILD, PAH and SSc associated renal or cardiac disease were numerically associated with hospitalization and severe outcome (Table 1). Univariable logistic analyses for hospitalization and severe outcome are shown in Figure 1. In multivariable logistic regression, age (OR 1.03, 95%CI 1.01-1.07, p=0.019), presence of non-SSc comorbidities (OR 2.52, 95%CI 1.16-5.47, p=0.019) and SSc-related renal disease (predicting success perfectly) were associated with hospitalization and for severe outcome age (OR 1.05, 95%CI 1.01-1.08).Conclusion:SSc patients at older age, with non-SSc comorbidities, SSc related renal disease or ILD are at risk of a more severe outcome and should follow precautions to avoid COVID-19 infections and need careful monitoring in case of COVID-19.Table 1.SSc disease characteristics of COVID-19 patientsAll(n=172)Hospitalized(n=67)Severe outcome(n=41)Age at COVID-19, yrs (SD)57 (14.0)63 (13.8)65 (12.2)Male sex, n (%)38 (21)18 (27)12 (29)≥1 comorbidity, n (%)63/176 (36)37 (55)30 (58)SSc disease duration at COVID, yrs (SD)11.5 (8.8)13.3 (9.7)12.7 (10.2)Diffuse cutaneous SSc, n (%)74 (42)29 (43)19 (46)mRSS, median (IQR)5 (8)5 (9)5 (7)ILD, n (%)90/175 (51)36/65 (55)26/40 (65)PAH, n (%)21/175 (12)11/65 (17)8/40 (20)GI disease, n (%)112/176 (64)45 (67)30 (73)Cardiac disease, n (%)37/166 (22)19/59 (32)16/36 (44)Musculoskeletal disease, n (%)40/175 (23)15/65 (23)6/40 (15)Renal disease, n (%)8/175 (5)7/65 (11)5/40 (13)Ever DU, n (%)69/175 (39)27/65 (42)14/40 (35)CRP, ng/ml (SD)35/177 (20)14 (21)9 (22)Immunosuppressive treatment, n (%)104/177 (59)41/66 (62)26 (63)Figure 1.Univariable logistic analyses for hospitalization and severe outcomeDisclosure of Interests:Anna-Maria Hoffmann-Vold Speakers bureau: Actelion, Boehringer Ingelheim, Roche, Merck Sharp & Dohme, ARXX, Lilly and Medscape, Consultant of: Actelion, Boehringer Ingelheim, Bayer, ARXX, and Medscape, Grant/research support from: Boehringer Ingelheim, Cathrine Brunborg: None declared, Francesca Tirelli: None declared, Patricia Carreira: None declared, Nicoletta Del Papa: None declared, Arsene Mekinian: None declared, Madelon Vonk: None declared, Alessandro Giollo: None declared, Giacomo De Luca: None declared, Maria De Santis: None declared, Corrado Campochiaro: None declared, Carina Mihai: None declared, Paolo Airò Speakers bureau: Bristol Myers Squibb, Bohringer Ingelheim, Consultant of: Bristol Myers Squibb, Bohringer Ingelheim, non-financial support from CSL Behring, SOBI, Janssen, Roche, Sanofi, Pfizer, Maria Grazia Lazzaroni: None declared, Elisabetta Zanatta: None declared, Rosario Foti: None declared, Yannick Allanore: None declared, Daniel Furst: None declared, Marco Matucci-Cerinic: None declared, Armando Gabrielli: None declared, Oliver Distler Speakers bureau: Actelion, Kymera Therapeutics, Mitsubishi Tanabe Pharma, Abbvie, Acceleron, Alexion, Amgen, AnaMar, Arxx Therapeutics, Baecon, Discovery, Blade Therapeutics, Corbus Pharmaceuticals, Drug Development International, Ltd, CSL Behring, Galapagos NV, Glenmark Pharmaceuticals, GSK, Horizon (Curzion) Pharmaceuticals, Inventiva, iQvia, Kymera Therapeutics, Lilly, Novartis, Pfizer, Topadur and UCB, Consultant of: Actelion, Kymera Therapeutics, Mitsubishi Tanabe Pharma, Abbvie, Acceleron, Alexion, Amgen, AnaMar, Arxx Therapeutics, Baecon, Discovery, Blade Therapeutics, Corbus Pharmaceuticals, Drug Development International, Ltd, CSL Behring, Galapagos NV, Glenmark Pharmaceuticals, GSK, Horizon (Curzion) Pharmaceuticals, Inventiva, iQvia, Kymera Therapeutics, Lilly, Novartis, Pfizer, Topadur and UCB, Grant/research support from: Boehringer Ingelheim